Drugs & Therapies

Aleniglipron (GSBR-1290) is an oral small-molecule GLP-1 receptor agonist from Structure Therapeutics, evaluated for weight loss in obesity in the Phase 2b ACCESS study.

Brensocatib is an oral, reversible DPP1 inhibitor that reduces the activity of neutrophil serine proteases, validated in bronchiectasis. Insmed has also evaluated it in other neutrophilic diseases, including chronic rhinosinusitis without nasal polyps (the BiRCh study).

Ceralasertib is an oral ATR kinase inhibitor that targets the DNA-damage response in cancer cells. AstraZeneca evaluated it in combination with the checkpoint inhibitor durvalumab in previously treated NSCLC (the LATIFY study).

Deramiocel (CAP-1002) is an allogeneic cardiosphere-derived cell therapy delivered by intravenous infusion. Capricor is developing it to slow the skeletal-muscle and cardiac decline of Duchenne muscular dystrophy.

Durvalumab (IMFINZI) is an anti-PD-L1 monoclonal antibody and a backbone of AstraZeneca's immuno-oncology franchise. It was combined with ceralasertib in the LATIFY NSCLC study.

Efgartigimod is an FcRn antagonist that lowers circulating IgG, including pathogenic autoantibodies. It is approved in generalized myasthenia gravis and has been evaluated in other IgG-mediated diseases, including thyroid eye disease (the UplighTED program).

FP-001 is a long-acting leuprolide mesylate depot formulated for six-month dosing intervals. Foresee is developing the 42 mg dose to suppress gonadotropins in children with central precocious puberty while reducing injection frequency.

GLPG3667 is an oral, selective TYK2 inhibitor from Galapagos evaluated across interferon-driven autoimmune diseases, including dermatomyositis (GALARISSO) and systemic lupus erythematosus (GALACELA).

Imlifidase is an IgG-cleaving enzyme (IdeS) that removes circulating IgG within hours. Hansa Biopharma evaluated it for rapidly clearing pathogenic autoantibodies in anti-GBM disease (the GOOD-IDES-02 study).

Inhaled alpha-1 antitrypsin delivers the protective protease inhibitor directly to the lungs. Kamada developed it to slow lung damage in alpha-1 antitrypsin deficiency.

JNJ-95475939 (JNJ-5939) is an investigational Johnson & Johnson candidate evaluated in the Phase 2b DUPLEX-AD study in atopic dermatitis.

Orforglipron is an oral, nonpeptide GLP-1 receptor agonist from Eli Lilly. As a once-daily pill it could broaden access to incretin-based weight loss beyond injectables, including weight maintenance after switching from semaglutide or tirzepatide.

Rezpegaldesleukin is a regulatory-T-cell-selective IL-2 conjugate designed to restore immune balance. Nektar has evaluated it in autoimmune diseases including alopecia areata (the REZOLVE-AA study) and atopic dermatitis.

Tinlarebant is an oral, once-daily RBP4 antagonist designed to reduce the retinal accumulation of toxic vitamin-A byproducts. It is Belite Bio's lead candidate for Stargardt disease and geographic atrophy.

Varegacestat (AL102) is an oral gamma-secretase inhibitor that suppresses Notch signaling. Immunome is developing it for progressing desmoid tumors, where it has shown high response rates.

The VIASKIN Peanut patch delivers controlled amounts of peanut protein through intact skin to desensitize allergic children. DBV is developing the 250 µg patch to reduce the severity of reactions on accidental exposure.

Zeleciment rostudirsen (DYNE-251) is a muscle-targeted antisense oligonucleotide that skips exon 51 of the DMD gene to restore partial dystrophin production. It is developed with Dyne's FORCE delivery platform for exon-51-amenable Duchenne muscular dystrophy.